aromatase inhibitors

Summary

Summary: Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.

Top Publications

  1. ncbi Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
  2. ncbi Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 28:509-18. 2010
  3. ncbi American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010
  4. ncbi Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
    Jose Baselga
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    J Clin Oncol 27:2630-7. 2009
  5. pmc Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients
    Dawn L Hershman
    Mailman School of Public Health, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA
    J Clin Oncol 28:4120-8. 2010
  6. pmc Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 126:529-37. 2011
  7. pmc Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
    Robert J Paridaens
    University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 26:4883-90. 2008
  8. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011
  9. ncbi Aromatase inhibitors in human lung cancer therapy
    Olga K Weinberg
    Department of Medicine, University of California at Los Angeles School of Medicine, 90095, USA
    Cancer Res 65:11287-91. 2005
  10. ncbi Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer
    Elizabeth J Folkerd
    Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 30:2977-80. 2012

Detail Information

Publications365 found, 100 shown here

  1. ncbi Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
    Thomas Bachelot
    Département de Cancérologie Médicale et Unité INSERM U590, Centre Leon Berard, 28 rue Laennec, 69373 Lyon Cedex 08, France
    J Clin Oncol 30:2718-24. 2012
    ..This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs).
  2. ncbi Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 28:509-18. 2010
    To conduct meta-analyses of randomized trials of aromatase inhibitors (AIs) compared with tamoxifen either as initial monotherapy (cohort 1) or after 2 to 3 years of tamoxifen (cohort 2).
  3. ncbi American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 28:3784-96. 2010
    ..To develop evidence-based guidelines, based on a systematic review, for endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer...
  4. ncbi Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
    Jose Baselga
    Medical Oncology Department, Vall d Hebron University Hospital, P Vall d Hebron, Barcelona, Spain
    J Clin Oncol 27:2630-7. 2009
    ..This study explored whether sensitivity to letrozole was enhanced with the oral mTOR inhibitor, everolimus (RAD001)...
  5. pmc Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients
    Dawn L Hershman
    Mailman School of Public Health, Columbia University Medical Center, 161 Fort Washington Ave, New York, NY 10032, USA
    J Clin Oncol 28:4120-8. 2010
    ..We investigated the rates and predictors of early discontinuation and nonadherence to hormonal therapy in patients enrolled in Kaiser Permanente of Northern California health system...
  6. pmc Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer
    Dawn L Hershman
    Department of Medicine and the Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia University Medical Center, 161 Fort Washington Avenue, 10 1068, New York, NY 10032, USA
    Breast Cancer Res Treat 126:529-37. 2011
    ..Both early discontinuation and non-adherence to HT were common and associated with increased mortality. Interventions to improve continuation of and adherence to HT may be critical to improve BC survival...
  7. pmc Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group
    Robert J Paridaens
    University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    J Clin Oncol 26:4883-90. 2008
    ....
  8. pmc Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based int
    Matthew J Ellis
    Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
    J Clin Oncol 29:2342-9. 2011
    ..To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations...
  9. ncbi Aromatase inhibitors in human lung cancer therapy
    Olga K Weinberg
    Department of Medicine, University of California at Los Angeles School of Medicine, 90095, USA
    Cancer Res 65:11287-91. 2005
    ..This work may lead to development of new treatment options for patients afflicted with NSCLC...
  10. ncbi Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer
    Elizabeth J Folkerd
    Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 30:2977-80. 2012
    To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) -..
  11. pmc Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial
    Marianne Ewertz
    Department of Oncology ME, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
    J Clin Oncol 30:3967-75. 2012
    ..7 years of median follow-up...
  12. pmc Novel aromatase inhibitors by structure-guided design
    Debashis Ghosh
    Department of Pharmacology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
    J Med Chem 55:8464-76. 2012
    Human cytochrome P450 aromatase catalyzes with high specificity the synthesis of estrogens from androgens. Aromatase inhibitors (AIs) such as exemestane, 6-methylideneandrosta-1,4-diene-3,17-dione, are preeminent drugs for the treatment ..
  13. ncbi Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1
    Jean McBryan
    Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
    Cancer Res 72:548-59. 2012
    b>Aromatase inhibitors (AI) are a standard-of-care treatment for postmenopausal, estrogen receptor-positive breast cancers. Although tumor recurrence on AI therapy occurs, the mechanisms underlying acquired resistance to AIs remain unknown...
  14. ncbi Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer
    Georgiana K Ellis
    Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:4875-82. 2008
    ..We investigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, to protect against aromatase inhibitor-induced bone loss...
  15. ncbi The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial
    Seyide Soysal
    Department of Obstetrics and Gynecology, Pamukkale University Medical Center, 20100 Denizli, Turkey
    Hum Reprod 19:160-7. 2004
    ....
  16. ncbi Clomiphene citrate or letrozole for ovulation induction in women with polycystic ovarian syndrome: a prospective randomized trial
    Ahmed Badawy
    Department of Obstetrics and Gynecology, Mansoura University, Mansoura, Egypt
    Fertil Steril 92:849-52. 2009
    ..To compare the effects of letrozole (5 mg) and clomiphene citrate (100 mg) for ovulation induction in women with polycystic ovary syndrome (PCOS)...
  17. ncbi Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT
    Stephen Chia
    Division of Medical Oncology, British Columbia Cancer Agency, University of British Columbia, 600 West 10 Avenue, Vancouver, BC, Canada
    J Clin Oncol 26:1664-70. 2008
    The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor-positive (HR+) breast cancer...
  18. ncbi Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial
    Ivana Sestak
    Cancer Research UK UK, Queen Mary University of London, London, United Kingdom
    J Clin Oncol 28:3411-5. 2010
    Third-generation aromatase inhibitors have been widely used in postmenopausal women for the adjuvant treatment of hormone receptor-positive breast cancer...
  19. pmc Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
    N Lynn Henry
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0942, USA
    Breast Cancer Res Treat 111:365-72. 2008
    b>Aromatase inhibitors (AIs) are increasingly used as adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. AIs are commonly associated with musculoskeletal symptoms...
  20. ncbi Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy
    Peyman Hadji
    Philipps University of Marburg, Department of Endocrinology, Reproductive Medicine and Osteoporosis, Germany
    Crit Rev Oncol Hematol 73:156-66. 2010
    ..comparisons difficult, this review evaluates the available data regarding compliance and persistence with adjuvant endocrine therapies for breast cancer (tamoxifen and aromatase inhibitors) and presents strategies for improving adherence.
  21. pmc Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
    Meredith M Regan
    International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Lancet Oncol 12:1101-8. 2011
    ..Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up...
  22. pmc Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
    ..a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.
  23. pmc Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial
    John M S Bartlett
    Endocrine Cancer Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Rd South, Edinburgh, EH4 2XR, United Kingdom
    J Clin Oncol 29:1531-8. 2011
    ....
  24. pmc Aromatase, aromatase inhibitors, and breast cancer
    Saranya Chumsri
    Department of Medicine, University of Maryland School of Medicine, and the Greenebaum Cancer Center, Baltimore, MD 21201, USA
    J Steroid Biochem Mol Biol 125:13-22. 2011
    ..Three aromatase inhibitors (AIs) are now FDA approved and have been shown to be more effective than the antiestrogen tamoxifen and are ..
  25. ncbi Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
    M Beeram
    Department of Medical Oncology, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Ann Oncol 18:1323-8. 2007
    ..How Akt modulates response is an area of significant clinical relevance...
  26. pmc The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer
    C J Fabian
    Breast Cancer Prevention Center, Division of Clinical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160 7418, USA
    Int J Clin Pract 61:2051-63. 2007
    The third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole have largely replaced tamoxifen as the preferred treatment for hormone receptor - positive breast cancer in postmenopausal women...
  27. ncbi Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
    Susan F Dent
    The Ottawa Hospital Cancer Centre, The University of Ottawa, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada
    Breast Cancer Res Treat 126:295-310. 2011
    b>Aromatase inhibitors (AIs) have been shown to reduce the risk of breast cancer recurrence and are widely used today as adjuvant therapy in women with early stage endocrine-responsive breast cancer...
  28. ncbi Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer
    M T Weigel
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Ann Oncol 24:126-33. 2013
    ..We aimed to determine its clinical relevance in aromatase inhibitor (AI)-resistant breast cancer...
  29. ncbi A randomized, placebo-controlled trial (NCIC CTG MAP.2) examining the effects of exemestane on mammographic breast density, bone density, markers of bone metabolism and serum lipid levels in postmenopausal women
    T Cigler
    Weill Cornell Medical College, New York, NY, USA
    Breast Cancer Res Treat 126:453-61. 2011
    ..Changes in lipid parameters on this trial were modest and reversible...
  30. ncbi Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study
    Judith M Bliss
    The Institute of Cancer Research, Sutton, UK
    J Clin Oncol 30:709-17. 2012
    ..Now, with longer follow-up, a large number of non-breast cancer-related events have been reported. Exploratory analyses describe breast cancer-free survival (BCFS) and explore incidence and patterns of the different competing events...
  31. ncbi Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentr
    Stephen Rd Johnston
    Royal Marsden NHS Foundation Trust, London, UK
    Lancet Oncol 14:989-98. 2013
    ..women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear...
  32. ncbi Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors
    D Dodwell
    Cookridge Hospital, Leeds LS16 6QB, West Yorkshire, UK
    Breast 15:584-94. 2006
    ..such as toremifene and raloxifene have poor efficacy following tamoxifen failure, whereas the non-steroidal aromatase inhibitors (AIs), anastrozole and letrozole and the steroidal AI exemestane are effective...
  33. ncbi A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
    Paul E Goss
    Division of Hematology Oncology, Princess Margaret Hospital, Toronto, ON, Canada
    N Engl J Med 349:1793-802. 2003
    ..The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy...
  34. ncbi Optimizing endocrine therapy for breast cancer
    Eric P Winer
    J Clin Oncol 23:1609-10. 2005
  35. ncbi Expression of estrogen receptor beta and phosphorylation of estrogen receptor alpha serine 167 correlate with progression-free survival in patients with metastatic breast cancer treated with aromatase inhibitors
    Kazuyoshi Motomura
    Department of Breast and Endocrine Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka University Graduate School of Medicine, Osaka, Japan
    Oncology 79:55-61. 2010
    ..0107). These data suggest that the expression of ERβ and phosphorylation of ERα Ser167 may be useful prognostic factors in patients with metastatic breast cancer who received first-line AI therapy...
  36. ncbi The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors
    H S Rugo
    University of California San Francisco, Comprehensive Cancer Center, San Francisco, USA
    Ann Oncol 19:16-27. 2008
    ..treatment for many years, we now have another option for postmenopausal women: the third-generation aromatase inhibitors (AIs) anastrozole, exemestane and letrozole...
  37. ncbi Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study
    Radhika K Ailawadi
    Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, Illinois, USA
    Fertil Steril 81:290-6. 2004
    ..To determine the role of an aromatase inhibitor, letrozole, in the treatment of reproductive-age women with endometriosis and associated chronic pelvic pain...
  38. ncbi A randomized trial of superovulation with two different doses of letrozole
    Raedah Al-Fadhli
    Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
    Fertil Steril 85:161-4. 2006
    ..The aim of this study was to evaluate the effects of either a 2.5-mg or a 5-mg daily dose of letrozole in women undergoing superovulation and intrauterine insemination (IUI)...
  39. ncbi Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor
    H M Fatemi
    Centre of Reproductive Medicine, AZ VUB, University Hospital, Dutch speaking Free University of Brussels, Laarbeeklaan 101, 1090 Brussels, Belgium
    Reprod Biomed Online 11:455-7. 2005
    ..Medical management of recurrent post-menopausal endometriosis with aromatase inhibitors seems to be an effective alternative treatment to surgery.
  40. ncbi Adjuvant aromatase inhibitor therapy: outcomes and safety
    Wolfgang Janni
    Klinikdirektor der Frauenklinik, Klinikum der Heinrich Heine Universität, Moorenstr 5, 40225 Dusseldorf, Germany
    Cancer Treat Rev 36:249-61. 2010
    Adjuvant therapy with the third-generation aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane has largely replaced the use of tamoxifen (TAM) as standard adjuvant endocrine treatment for postmenopausal women with hormone-..
  41. ncbi Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study
    Karine Briot
    Rheumatology Department, Cochin Hospital, Rheumatology Department, Paris Descartes University, 27 rue Faubourg Saint Jacques, 75014, Paris, France
    Breast Cancer Res Treat 120:127-34. 2010
    The objective of the present study was to evaluate the effect of the switch of aromatase inhibitors (AIs) on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer...
  42. ncbi A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health
    Michael S Ewer
    Department of Cardiology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1813-26. 2009
    ..an important component of endocrine therapy for breast cancer, although major clinical trials of the aromatase inhibitors (AIs) anastrozole, letrozole, and exemestane suggest that these agents are more effective and better ..
  43. ncbi Letrozole and norethisterone acetate in colorectal endometriosis
    Simone Ferrero
    Department of Obstetrics and Gynaecology, San Martino Hospital and University of Genoa, Genoa, Italy
    Eur J Obstet Gynecol Reprod Biol 150:199-202. 2010
    ..This study evaluates the efficacy of aromatase inhibitors and norethisterone acetate in treating pain and gastrointestinal symptoms caused by bowel endometriosis.
  44. ncbi Aromatase inhibitors for female infertility: a systematic review of the literature
    Nikolaos P Polyzos
    PACMeR Panhellenic Association for Continual Medical Research, Section of Obstetrics and Gynaecology and Public Health, Athens 10438, Greece
    Reprod Biomed Online 19:456-71. 2009
    ..b>Aromatase inhibitors (AI) have been introduced as a new treatment option that could challenge CC for ovulation induction...
  45. ncbi Letrozole and desogestrel-only contraceptive pill for the treatment of stage IV endometriosis
    Valentino Remorgida
    Department of Obstetrics and Gynaecology, San Martino Hospital and University of Genoa, Genoa, Italy
    Aust N Z J Obstet Gynaecol 47:222-5. 2007
    It has recently been suggested that aromatase inhibitors may effectively reduce pain symptoms related to the presence of endometriosis both in postmenopausal women and in subjects of reproductive age.
  46. pmc Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels
    Sherri Ann M Burnett-Bowie
    Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 94:4785-92. 2009
    ..Aging is associated with declining gonadal steroid production, low bone mineral density (BMD), and fragility fractures. The efficacy and safety of testosterone replacement in older men remains uncertain...
  47. ncbi Aromatase inhibitors in the treatment of severe endometriosis
    Noha A Mousa
    Institute of Medical Science, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Obstet Gynecol 109:1421-3. 2007
    ..Endometriosis-associated chronic pelvic pain unresponsive to surgical menopause is a difficult clinical problem...
  48. ncbi Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis
    S Ferrero
    Department of Obstetrics and Gynaecology, San Martino Hospital and University of Genoa, Largo R Benzi 1 16132, Genoa, Italy
    Hum Reprod 24:3033-41. 2009
    The available data on effectiveness of aromatase inhibitors in treating pain symptoms related to endometriosis is limited...
  49. ncbi Aromatase inhibitors in breast cancer
    Stephen Hiscox
    Welsh School of Pharmacy, Cardiff University, Cardiff, UK
    Maturitas 63:275-9. 2009
    ..Clinical data demonstrate that these aromatase inhibitors are superior to tamoxifen as adjuvant therapy for breast cancer and have now replaced tamoxifen as first ..
  50. ncbi Pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate in unexplained infertility
    Ahmed Badawy
    Department of Obstetrics and Gynecology, Mansoura University, Egypt
    Acta Obstet Gynecol Scand 88:187-91. 2009
    To evaluate the pregnancy outcome after ovulation induction with aromatase inhibitors or clomiphene citrate (CC).
  51. ncbi Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome
    Michel Laroche
    Service de Rhumatologie, CHU Rangueil, 1 avenue Jean Poulhes, Toulouse, France
    J Rheumatol 34:2259-63. 2007
    ..have undergone surgery for breast cancer and who require adjuvant hormone therapy are often treated with aromatase inhibitors. With these treatments, joint pain is frequent (30% to 40%) and quite often disabling (5% to 10%)...
  52. ncbi Letrozole and norethisterone acetate in rectovaginal endometriosis
    Valentino Remorgida
    Department of Obstetrics and Gynecology, San Martino Hospital and University of Genoa, Genoa, Italy
    Fertil Steril 88:724-6. 2007
    ....
  53. ncbi Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
    Danijela Jelovac
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Cancer Res 65:5380-9. 2005
    ..These results indicate that blocking both ER- and growth factor-mediated transcription resulted in the most effective inhibition of growth of ER-positive breast cancer cells...
  54. ncbi Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial
    Georg Pfeiler
    Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    J Clin Oncol 29:2653-9. 2011
    b>Aromatase inhibitors are effective as endocrine treatment for patients with hormone receptor-positive breast cancer...
  55. pmc Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
    Marion T Weigel
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res 14:R78. 2012
    ..Estrogen (E) mediates its effects by binding to the ER. Therapies targeting the estrogenic stimulation of tumor growth reduce mortality from ER+ breast cancer. However, resistance remains a major clinical problem...
  56. pmc Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, United States
    Steroids 72:7-25. 2007
    ..Developing drugs that target the estrogen receptor (ER) either directly (tamoxifen) or indirectly (aromatase inhibitors) has improved the prognosis of breast cancer and significantly advanced healthcare...
  57. ncbi Aromatase cytochrome P450 and extragonadal estrogen play a role in ischemic neuroprotection
    Louise D McCullough
    Department of Neurology and Anesthesiology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287 4961, USA
    J Neurosci 23:8701-5. 2003
    ....
  58. ncbi Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer
    Katherine D Crew
    Columbia University, 161 Fort Washington Ave, 10 1068, New York, NY 10032, USA
    J Clin Oncol 28:1154-60. 2010
    PURPOSE Women with breast cancer (BC) treated with aromatase inhibitors (AIs) may experience joint symptoms that can lead to discontinuation of effective therapy...
  59. ncbi Differential effects of androgens and estrogens on bone turnover in normal men
    Benjamin Z Leder
    Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 88:204-10. 2003
    ..These data also suggest that androgens may play an important role in the regulation of bone formation in men...
  60. ncbi Aromatase inhibitors in the treatment of breast cancer
    Robert W Brueggemeier
    College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, Ohio 43210 1291, USA
    Endocr Rev 26:331-45. 2005
    ..Nonsteroidal aromatase inhibitors can be divided into three classes: aminoglutethimide-like molecules, imidazole/triazole derivatives, and ..
  61. ncbi Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group
    David M Reid
    Department of Rheumatology, University of Aberdeen, United Kingdom
    Cancer Treat Rev 34:S3-18. 2008
    In postmenopausal women, the use of aromatase inhibitors increases bone turnover and induces bone loss at sites rich in trabecular bone at an average rate of 1-3% per year leading to an increase in fracture incidence compared to that seen ..
  62. ncbi Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome
    Leilani Morales
    Department of Obstetrics and Gynecology, Division of Gynecological Oncology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 26:3147-52. 2008
    Arthralgia is an adverse class effect of aromatase inhibitors (AIs). To date, its exact mechanism remains unclear...
  63. ncbi History of aromatase: saga of an important biological mediator and therapeutic target
    R J Santen
    University of Virginia Health System, Division of Endocrinology, P O Box 801416, Charlottesville, Virginia 22908, USA
    Endocr Rev 30:343-75. 2009
    ..Two general approaches ultimately led to the development of potent and selective aromatase inhibitors. One targeted the enzyme using analogs of natural steroidal substrates to work out the relationships ..
  64. pmc Use of letrozole in assisted reproduction: a systematic review and meta-analysis
    Antonio Requena
    IVI Madrid, Santiago de Compostela 88, E 28035 Madrid, Spain
    Hum Reprod Update 14:571-82. 2008
    ..AIs induce ovulation by inhibiting estrogen production; the consequent hypoestrogenic state increases GnRH release and pituitary follicle-stimulating hormone (FSH) synthesis...
  65. ncbi Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial
    Andreas Polychronis
    Cancer Research UK Laboratories, Department of Cancer Medicine, Imperial College, London, UK
    Lancet Oncol 6:383-91. 2005
    ..Some oestrogen-receptor (ER) positive breast cancers express epidermal growth factor receptor (EGFR), but whether inhibition of EGFR can suppress proliferation of breast cancer cells and ER function is not known...
  66. ncbi A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report
    S K Goswami
    Institute of Reproductive Medicine, Salt Lake, Kolkata 700091, India
    Hum Reprod 19:2031-5. 2004
    ..Use of letrozole, a selective inhibitor of aromatase, reduces the gonadotrophin dose required to induce follicular maturation. We evaluated whether incorporation of letrozole could be an effective low-cost IVF protocol for poor responders...
  67. ncbi A new era in ovulation induction
    Hananel Holzer
    Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
    Fertil Steril 85:277-84. 2006
    To evaluate the efficacy of aromatase inhibitors in ovulation induction, superovulation, and IVF.
  68. ncbi An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer
    Katrine L Henriksen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen Ø, Denmark
    Acta Oncol 48:522-31. 2009
    ....
  69. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
    ..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects...
  70. ncbi Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: brief report and review of the literature
    Mariam M Alhilli
    Department of Obstetrics and Gynecology Medical Oncology Obstetrics and Gynecology, Division of Gyencologic Oncology, Mayo Clinic, Rochester, Minnesota, USA
    J Obstet Gynaecol Res 38:340-4. 2012
    ..However, hormonal suppression with aromatase inhibitors, which have shown promising results, may be a viable alternative to these modalities...
  71. ncbi Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
    Sekwon Jang
    Division of Hematology, Oncology and Transplantation, University of Minnesota, 14 142 PWB, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455, USA
    Breast Cancer Res Treat 121:273-9. 2010
    To determine whether authors conducting economic analyses of aromatase inhibitors in breast cancer are less likely to reach unfavorable conclusions if the economic study is sponsored by the manufacturer of the drug...
  72. ncbi Ovulation induction management of PCOS
    David S Guzick
    University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Clin Obstet Gynecol 50:255-67. 2007
    ..In clomiphene-resistant women, alternative treatments include adjunctive metformin or dexamethasone, aromatase inhibitors, or ovarian drilling...
  73. ncbi Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
    Norikazu Masuda
    National Hospital Organization, Osaka National Hospital, Osaka, Japan
    Lancet Oncol 13:345-52. 2012
    b>Aromatase inhibitors have shown increased efficacy compared with tamoxifen in postmenopausal early breast cancer...
  74. ncbi Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients
    Roberta Ferraldeschi
    Department of Medical Oncology, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK
    Breast Cancer Res Treat 133:1191-8. 2012
    ..The aim was to investigate whether polymorphic variation of CYP19A1 and enzymes involved in estrogen and aromatase inhibitors (AIs) metabolism are associated with efficacy of AIs...
  75. ncbi Neoadjuvant endocrine therapy in breast cancer
    C Abrial
    Centre Jean Perrin, 58 rue Montalembert, BP 392, 63011 Clermont Ferrand Cedex 1, France
    Breast 15:9-19. 2006
    ..This article reviews the studies published on neoadjuvant endocrine treatment (tamoxifen and aromatase inhibitors). According to the literature, neoadjuvant endocrine therapy seems to be effective and well tolerated...
  76. pmc Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial
    G Pfeiler
    Division of Gynecology and Gynecological Oncology, Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria
    Br J Cancer 108:1408-14. 2013
    There exists evidence that body mass index (BMI) impacts on the efficacy of aromatase inhibitors in patients with breast cancer. The relationship between BMI and the efficacy of tamoxifen is conflicting...
  77. ncbi Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis
    P Hadji
    Department of Gynecology, Endocrinology and Oncology, Phillips University of Marburg, Marburg, Germany
    Breast Cancer Res Treat 138:185-91. 2013
    ..The aim of our study was to analyze the persistence with tamoxifen (TAM) and aromatase inhibitors (AI) in postmenopausal women with hormone-receptor-positive BC and to identify determinants of non-..
  78. ncbi A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene
    W Yue
    Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore 21201
    Cancer Res 54:5092-5. 1994
    ..When ovariectomized mice with MCF-7Ca tumors supplemented with androstenedione were treated with aromatase inhibitors 4-hydroxyandrostenedione (1 mg/mouse/day, s.c.) or CGS 16949A (0.5 mg/mouse/day, s.c...
  79. pmc AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies
    Cynthie Wong
    Division of Tumor Cell Biology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA
    Breast Cancer Res Treat 134:671-81. 2012
    b>Aromatase inhibitors (AI) are currently the first line therapy for estrogen receptor (ER)-positive postmenopausal women...
  80. ncbi Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer
    H Anderson
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Ann Oncol 22:1770-6. 2011
    Surprisingly few data are published on the relevance of even commonly used biomarkers of response to aromatase inhibitors (AIs) in advanced breast cancer...
  81. ncbi The importance of nonpharmacogenetic factors in endocrine therapy
    Colin McCowan
    Dundee Cancer Centre, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
    Pharmacogenomics 13:721-8. 2012
    ..Side effects from tamoxifen or aromatase inhibitors may lead to patients stopping or switching therapy, while comorbidities, consequent coprescribing and ..
  82. pmc Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:319-28. 2010
    Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and aromatase inhibitors (AI) are employed widely for endocrine therapy in postmenopausal women with breast cancer...
  83. ncbi Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis
    Myrthe P P van Herk-Sukel
    PHARMO Institute for Drug Outcomes Research, P O Box 85222, 3508 AE, Utrecht, The Netherlands
    Breast Cancer Res Treat 122:843-51. 2010
    ..rates on tamoxifen, but lack information on the continuance of any endocrine treatment [both tamoxifen and aromatase inhibitors (AIs)] within the same cohort...
  84. ncbi Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen
    Diana E Ramirez-Ardila
    Department of Medical Oncology, Erasmus MC Cancer Institute, Room Be424, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 139:39-49. 2013
    ..receptor (ER)-positive patients with metastatic disease treated with first-line tamoxifen (N = 447) or aromatase inhibitors (AIs; N = 84). We detected in 423 patients hotspot mutations for PIK3CA (31 %)...
  85. ncbi New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation
    Carla Varela
    CEF, Center for Pharmaceutical Studies, Pharmaceutical Chemistry Group, Faculty of Pharmacy, University of Coimbra, 3000 548 Coimbra, Portugal
    J Med Chem 55:3992-4002. 2012
    ..In addition, IFD simulations helped to explain the recognition of the C-3 hydroxyl derivatives (1 and 2) as well as 15 within the enzyme...
  86. ncbi Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
    L Perey
    Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland
    Ann Oncol 18:64-9. 2007
    ..The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment...
  87. pmc New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 18:S10-7. 2009
    ..to long term therapy with the selective oestrogen receptor modulators (SERMs, tamoxifen and raloxifene) and aromatase inhibitors. The question to be addressed is how we can amplify the new biology of oestrogen-induced apoptosis to ..
  88. pmc Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study
    Marco Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 29:1117-24. 2011
    ..We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy...
  89. pmc Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover
    Huan Jin
    School of Public Health, Fudan University, Shanghai, China
    J Clin Oncol 30:718-21. 2012
    ..5 years. Efficacy was difficult to assess because more than 60% of placebo patients crossed over to letrozole after being unblinded...
  90. pmc Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole
    Tatiana M Prowell
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Prev Res (Phila) 4:1993-2001. 2011
    ..Adjuvant aromatase inhibitors are associated with a reduction in incidence of contralateral breast cancer...
  91. pmc Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer
    Alfred I Neugut
    Herbert Irving Comprehensive Cancer Center, College of Physiciansand Surgeons, Columbia University, New York, NY, USA
    J Clin Oncol 29:2534-42. 2011
    ..Noncompliance with adjuvant hormonal therapy among women with breast cancer is common. Little is known about the impact of financial factors, such as co-payments, on noncompliance...
  92. ncbi High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer
    Yumi Endo
    Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho cho, Mizuho ku, Nagoya, 467 8601, Japan
    Int J Clin Oncol 16:512-8. 2011
    b>Aromatase inhibitors have played a central role in endocrine therapy for estrogen receptor (ER)-positive breast cancer in postmenopausal women...
  93. ncbi Endogenous estrogens influence endothelial function in young men
    Robert Lew
    Baker Medical Research Institute and Alfred Hospital, Prahran, Victoria, Australia
    Circ Res 93:1127-33. 2003
    ..Our results suggest that endogenous estrogens play a direct regulatory role in endothelial function in young healthy men...
  94. ncbi Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy
    Manfred Kaufmann
    Klinik fur Gynakologie und Geburtshilfe, J W Goethe Universität Frankfurt am Main, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    J Cancer Res Clin Oncol 131:487-94. 2005
    ..The third-generation aromatase inhibitors, which are highly selective and potent in suppressing whole-body estrogen synthesis in postmenopausal women,..
  95. ncbi Aromatase inhibitors from Broussonetia papyrifera
    D Lee
    Program for Collaborative Research in the Pharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60612, USA
    J Nat Prod 64:1286-93. 2001
    ..7), were isolated and characterized, but proved to be inactive as aromatase inhibitors, as were an additional 21 known compounds...
  96. ncbi Pharmacogenetics of endocrine therapy for breast cancer
    Michaela J Higgins
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Annu Rev Med 62:281-93. 2011
    ..Emerging data suggest that host factors may also predict interpatient variability in response to aromatase inhibitors.
  97. ncbi The evolving role of aromatase inhibitors in breast cancer
    Kefah Mokbel
    St George s Hospital and Medical School, London SW17 0QT, UK
    Int J Clin Oncol 7:279-83. 2002
    ..This article reviews the recent evidence regarding the role of third-generation aromatase inhibitors in the management of breast cancer...
  98. ncbi Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach
    Andrea Cavalli
    Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro, 6, I 40126 Bologna, Italy
    J Med Chem 48:7282-9. 2005
    To identify enantioselective nonsteroidal aromatase inhibitors, a multidisciplinary medicinal chemistry approach was pursued. First, our earlier CoMFA model [Bioorg. Med. Chem...
  99. ncbi New approaches to the understanding of tamoxifen action and resistance
    L M Berstein
    Department of Medicine, Division of Endocrinology and Metabolism, University of Virginia, PO Box 801416, Charlottesville, VA 22908, USA
    Endocr Relat Cancer 10:267-77. 2003
    ....
  100. ncbi Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer
    Qingzhong Hu
    Pharmaceutical and Medicinal Chemistry, Saarland University and Helmholtz Institute for Pharmaceutical Research Saarland HIPS, Campus C2 3, P O Box 151150, D 66123 Saarbrucken, Germany
    J Med Chem 55:7080-9. 2012
    ..These compounds showed also good selectivity toward CYP11B1 (selectivity factors (IC(50 CYP11B1)/IC(50 CYP11B2)) around 50) and CYP17 (no inhibition)...
  101. ncbi Aromatase and other steroidogenic genes in endometriosis: translational aspects
    E Attar
    Division of Reproductive Biology Research, Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Hum Reprod Update 12:49-56. 2006
    ..These basic findings led to recent phase-II studies employing aromatase inhibitors in the treatment of endometriosis...

Research Grants69

  1. Development of VN/14-1 and Related Analogs for Breast Cancer Therapy
    VINCENT COLLINS OFUKA NJAR; Fiscal Year: 2013
    ..e., tumors that are resistant to mainstay breast cancer therapies such as tamoxifen and aromatase inhibitors) breast cancer xenograft models...
  2. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2011
    ..and limiting toxicity of chemo-preventive agents which include selective estrogen receptor antagonists, aromatase inhibitors, retinoids, COX-2 inhibitors and metformin...
  3. RCT of exercise on aromatase inhibitor side effects in breast cancer survivors
    Melinda L Irwin; Fiscal Year: 2012
    ..adjuvant hormonal therapy for women with early- stage, hormone receptor-positive breast cancer, the aromatase inhibitors (AI's) have rapidly supplanted tamoxifen as the hormonal therapy of choice...
  4. Optic Nerve Aging and Glaucoma
    Thasarat Vajaranant; Fiscal Year: 2013
    ..training and line of research will provide a foundation for future studies investigating the effects of aromatase inhibitors, selective estrogen receptor modulators and other anti- estrogen treatments on the optic nerve...
  5. Lifestyle and Molecular Factors of Bone Health in Breast Cancer Survivors
    Song Yao; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) have been rapidly replacing tamoxifen (TAM) as first-line adjuvant hormonal therapy for postmenopausal women diagnosed with hormone receptor (HR)-positive, early-stage ..
  6. A Novel Target for the Treatment of Endometriosis
    Paul D Crowe; Fiscal Year: 2011
    ..Reports that aromatase inhibitors, which block the final step of estrogen synthesis, are effective in rare cases of post-menopausal ..
  7. Theranostic Nanomedicine for Breast Cancer Prevention and Image-Guided Therapy
    Prakash R Rai; Fiscal Year: 2013
    ..and limiting toxicity of chemo-preventive agents which include selective estrogen receptor antagonists, aromatase inhibitors, retinoids, COX-2 inhibitors and metformin...
  8. Acupuncture for Aromatase Inhibitor-Related Arthralgias in Breast Cancer Patients
    Dawn Hershman; Fiscal Year: 2013
    Third generation aromatase inhibitors have been shown to be superior to tamoxifen in improving disease free survival, decreasing distant and local recurrence rates and decreasing incidence of contra-lateral breast cancer in women with ..
  9. CYP19A1 gene and Pharmacogenetics of Response
    REINA C VILLAREAL; Fiscal Year: 2013
    ..found to influence changes in BMD in response to hormone therapy in postmenopausal women and bone loss from aromatase inhibitors in women with breast cancer...
  10. Aromatase Inhibitors in Pulmonary Vascular Complications of Liver Disease
    Steven M Kawut; Fiscal Year: 2013
    ..This research would provide the ideal training ground for young investigators interested in POR in PVD who wish to study novel therapeutics for [unreadable]orphan[unreadable] diseases. ..
  11. Endothelial Aromatase in Sex-Specific Cerebrovascular Dysfunction After Ischemia
    KRISTEN LEANNE ZULOAGA; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: Aromatase inhibitors, which are in use clinically for the treatment of hormone positive breast cancer, have been linked to ..
  12. Brain aromatase availability in steroid users: PET studies with [11C]vorozole
    Thomas B Hildebrandt; Fiscal Year: 2013
    ..also provide data to develop novel therapeutic targets to prevent and treat AAS addiction;specifically, aromatase inhibitors and estrogen antagonists may be used as pharmacological agents to treat AAS intoxication...
  13. Targeting the Obesity-Inflammation-COX-Aromatase Axis to Lower Breast Cancer Risk
    ANDREW JESS DANNENBERG; Fiscal Year: 2013
    ..deprivation is a commonly used approach for breast cancer prevention and treatment, but both SERMs and aromatase inhibitors have significant side effects that restrict their widespread use for prophylaxis...
  14. The new biology of estrogen action in aromatase resistance breast cancer cells
    JOAN SUEDEE LEWIS-WAMBI; Fiscal Year: 2011
    ..Project Summary: Aromatase inhibitors (Als) are currently accepted as the standard care for the treatment of estrogen receptor (ER)-positive ..
  15. MicroRNA Signature of Tamoxifen Resistance in Breast Cancer
    Sarmila Majumder; Fiscal Year: 2010
    ..Recently, alternative endocrine therapies, such as aromatase inhibitors (AI), are found to be more effective in estrogen receptor positive, post-menopausal women with breast ..
  16. Personalized therapeutics for inhibiting breast cancer metastasis
    DEBRA AUGUSTE; Fiscal Year: 2012
    ..and human epidermal growth receptor-2 (HER2) on their surface are treated with hormone (anti-estrogen or aromatase inhibitors) or targeted (Herceptin) therapies, respectively...
  17. Oral Health in Breast Cancer Survivors on Aromatase Inhibitors
    Linda Susan Taichman; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) are routinely prescribed as adjuvant hormonal therapy for postmenopausal women with hormone receptor positive breast cancer...
  18. Structure and Function of Integral Membrane Enzyme Human Aromatase
    Debashis Ghosh; Fiscal Year: 2012
    ..We propose a research plan to unravel the molecular details of how aromatase works and how aromatase inhibitors prevent it from making estrogens...
  19. Fractures, Heart Disease, and Stroke on Aromatase Inhibitors
    Nancy L Keating; Fiscal Year: 2010
    ..Recently, randomized controlled trials identifying substantial benefits of aromatase inhibitors for early- stage cancers have led to national recommendations that every postmenopausal woman with an ..
  20. Epigenetic Regulation of Breast Cancer Progression by the Proto-oncogene PELP1
    MONICA MANN; Fiscal Year: 2013
    ..Endocrine therapies using tamoxifen and aromatase inhibitors substantially improve disease- free survival, however, initial or acquired resistance frequently occurs...
  21. Mechanisms of Breast Tumor Cell Growth, Motility, and Antiestrogen Response
    Amy H Bouton; Fiscal Year: 2013
    ..hormonal therapies designed to inhibit receptor function (antiestrogens) or block production of estrogens (aromatase inhibitors)...
  22. Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
    Robert A Gatenby; Fiscal Year: 2013
    ..combine three chemotherapeutic strategies currently used in the clinic: (a) hormonal therapy (tamoxifen and aromatase inhibitors), (b) targeted therapy (herceptin), and (c) standard chemotherapy (doxorubicin and taxol)...
  23. A Hypersensitive ER alpha Mutant in Breast Cancer Hormone Resistance
    Suzanne Aw Fuqua; Fiscal Year: 2012
    ..tumors re- gress but then regrow, suggesting that the mutation also confers resistance to therapies such as aromatase inhibitors (AIs)...
  24. A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
    JOYCE MARIE contact SLINGERLAND; Fiscal Year: 2010
    ..1 (ER) is expressed in 70% of new breast cancers but de novo and acquired resistance to tamoxifen or aromatase inhibitors (AI) limit their efficacy...
  25. The role of the mTOR signaling pathway in ER-positive breast cancer
    MARINA KAUFMAN HOLZ; Fiscal Year: 2013
    ..ER-positive breast cancers can be targeted therapeutically by antiestrogens (such as tamoxifen) or aromatase inhibitors (AIs)...
  26. Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ER
    Christopher Benz; Fiscal Year: 2013
    ..ER (designated ER+), signifying that they MAY respond favorably to endocrine therapy with tamoxifen or aromatase inhibitors. Although low ER expressing tumors (ER-) are almost invariably unresponsive to such therapies, the ..
  27. Cognitive Functioning After Breast Cancer Treatment
    Patricia A Ganz; Fiscal Year: 2010
    ..radiation, chemotherapy) and who are about to initiate adjuvant endocrine therapy (with tamoxifen or aromatase inhibitors)...
  28. Role of pharmacogenetics on exemestane metabolism and toxicity
    Philip Lazarus; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Aromatase inhibitors (AIs) are widely used as adjuvant treatment for estrogen-receptor positive breast cancer in post-menopausal women...
  29. LRH-1 Antagonism: Impact on Estrogen-dependent Breast Cancer
    Marcia I Dawson; Fiscal Year: 2013
    ..would locally reduce estrogen levels compared to adjuvant therapeutics such as estrogen antagonists and aromatase inhibitors and, thereby, attenuate the adverse systemic effects caused by whole-body estrogen ablation...
  30. Second line breast cancer therapy through a novel Phytoantiestrogen
    SYREETA LATATIA TILGHMAN; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Although aromatase inhibitors, such as letrozole, are the standard endocrine therapy of choice for post-menopausal women with early-stage metastatic estrogen-dependent breast cancer, the major ..
  31. Next generation bisphosphonates for chemo- and immuno-therapy
    Eric Oldfield; Fiscal Year: 2013
    ..bisphosphonate drug zoledronate has unexpected positive effects as an adjuvant (in combination therapy with aromatase inhibitors) in breast cancer, reducing the re-occurrence of disease (at any site) by 36%, in addition to increasing ..
  32. Mechanisms Underlying SES Disparities in Breast Cancer Mortality
    Liliana E Pezzin; Fiscal Year: 2013
    ..breast conserving surgery with radiotherapy, the choice and use of alternative adjuvant endocrine therapy (aromatase inhibitors vs. tamoxifen) and possibly persistence with endocrine therapy once initiated...
  33. Vitamin D3 Effects on Musculoskeletal Symptoms with Use of Aromatase Inhibitors
    Alice C Shapiro; Fiscal Year: 2012
    ..determine the efficacy and safety of vitamin D3 supplements for reducing side effects of treatment with aromatase inhibitors in women with breast cancer...
  34. Hormonal regulation of the brain microenvironment and its contribution to brain m
    Diana M Cittelly; Fiscal Year: 2013
    ..Importantly, aromatase inhibitors and anti-estrogens used for the treatment of ER+ tumors can cross the blood brain barrier and could be ..
  35. Nsaid Effects on Clinical and Imaging Breast Biomarkers
    PATRICIA ANN THOMPSON; Fiscal Year: 2013
    ..b>Aromatase inhibitors (AI) are recommended as first-line adjuvant therapy for hormone responsive tumors in postmenopausal women...
  36. COLORADO REPRODUCTIVE MEDICINE UNIT
    Ruben Alvero; Fiscal Year: 2013
    ..Use of aromatase inhibitors in men leads to improvement of compromised sperm parameters and reproductive hormones but pregnancy data is ..
  37. Androgens and musculoskeletal symptoms among breast cancer patients on aromatase
    Lisa Gallicchio; Fiscal Year: 2010
    b>Aromatase inhibitors, which suppress the production of estrogens by binding to the aromatase enzyme, have become the hormonal adjuvant treatment of choice for postmenopausal breast cancer...
  38. Estrogen Deprivation and Aromatase Inhibitor associated Arthralgia
    Jun J Mao; Fiscal Year: 2013
    ..joint pain) occurrence, severity, and functional interference among postmenopausal women receiving aromatase inhibitors (AIs) as adjuvant therapy for early stage breast cancer...
  39. Treatment of vulvo-vaginal atrophy with a novel formulation of Tamoxifen
    Fred Mermelstein; Fiscal Year: 2012
    ..The patient population includes 600,000 menopausal aged women in the United States currently using aromatase inhibitors ("AI therapy") to prevent breast cancer recurrence...
  40. Endocrine resistance in breast cancer
    ROBERT R CLARKE; Fiscal Year: 2013
    ..of how cellular signaling to regulate cell fate is differentially affected by estrogens, antiestrogens, and aromatase inhibitors in sensitive and resistant breast cancers...
  41. Development of Breast Cancer Risk Model Based on Estrogen Metabolomics
    Richard J Santen; Fiscal Year: 2013
    ..We anticipate reducing the number of women needed to be treated to prevent one breast cancer from 50 to 13 with tamoxifen and to 5.with aromatase inhibitors.
  42. The Mechanism of BRCA1 in Tumor Suppression
    Yanfen Hu; Fiscal Year: 2010
    ..Given that aromatase inhibitors have become one of the most effective drugs in breast cancer treatment, the proposed work promises to ..
  43. Decision making on aromatase inhibitors in breast cancer survivors 65 and older
    HUIBRIE CHRISTELLE PIETERS; Fiscal Year: 2013
    ..What contributes to discontinuation is poorly understood. Aromatase inhibitors (AIs) are associated with adverse side effects such as an arthralgia syndrome, hot flashes, loss of bone ..
  44. Genetic Predictors of Anti-Estrogen Clinical Activity in Breast Cancer Patients
    James Michael Rae; Fiscal Year: 2013
    ..therapies including the Selective Estrogen Receptor Modulator (SERM) tamoxifen, and the 3rd generation aromatase inhibitors (AI) including anastrozole, letrozole, and exemestane have clearly played a substantial role in decreasing ..
  45. [11C]vorozole as a PET tracer for in vivo studies of human aromatase
    Anat Biegon; Fiscal Year: 2012
    ..aromatase non-invasively will have a dramatic impact on the ability to select patients who can benefit from aromatase inhibitors (AI) in different diseases, facilitate AI treatment monitoring and provide a tool for new AI drug ..
  46. 18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrent
    Stephen Chia; Fiscal Year: 2010
    ..curable however, and virtually all patients will eventually develop resistance to both tamoxifen and the aromatase inhibitors. Fulvestrant is a new pure estrogen receptor antagonist which binds with high affinity to the estrogen ..
  47. Breast Cancer Survivors: Physical Activity, Inflammation, Fatigue, and Distress
    Janice K Kiecolt-Glaser; Fiscal Year: 2012
    ..40 and older;the women will have completed cancer treatment within the past year (except for tarnoxifen/aromatase inhibitors), and will be at least two months post surgery or adjuvant therapy or radiation, whichever occurred last...
  48. Targeting endocrine resistant breast cancer with anacardic acid
    David Schultz; Fiscal Year: 2013
    ..g., tamoxifen (TAM)) and aromatase inhibitors (AI, e.g. letrozole) against which tumor cells become resistant...
  49. Action of RB Pathway in Breast Cancer Therapy
    Erik Knudsen; Fiscal Year: 2013
    ..g. tamoxifen) or through ER ligand depletion strategies (e.g. aromatase inhibitors)...
  50. TRANSLATIONAL RESEARCH IN BREAST CANCER
    C Kent Osborne; Fiscal Year: 2012
    ..the androgen receptor may be an important cause of resistance to endocrine therapy with either tamoxifen or aromatase inhibitors. We will seek the mechanisms behind this interaction, and will initiate a clinical trial designed to ..
  51. AROMATASE AND BREAST CANCER
    Angela M Brodie; Fiscal Year: 2013
    ..The aromatase inhibitors we pioneered in the early phases of this grant are now proving to be of value in the clinic...
  52. Obesity and Endocrine Therapy Resistance in Postmenopausal Mammary Tumorigenesis
    REBECCA E DE ANGEL; Fiscal Year: 2010
    ..b>Aromatase inhibitors (Als) are a promising class of drug for postmenopausal breast cancer treatment that decreases estrogen ..
  53. Novel Direct Approaches Toward Bioactive Heterocycles
    Vladimir Gevorgyan; Fiscal Year: 2013
    ..potential topoisomerase I inhibitors, and tetra- and pentacyclic heterocyclic skeletons, potential QR2 and aromatase inhibitors. The synthetic part of the proposed work toward selected targets is essential as it may lead to discovery ..
  54. Aromatase Inhibitor in Males with Adrenal Hyperplasia
    Kyriakie Sarafoglou; Fiscal Year: 2006
    ..b>Aromatase inhibitors have selective action, are well tolerated by patients, and do not interfere with the production of steroid ..
  55. Measures of Endocrine Sensitivity in Early Breast Cancer
    Hannah M Linden; Fiscal Year: 2010
    ..Recently aromatase inhibitors (AIs) have been shown to provide incremental benefit over tamoxifen...
  56. Flaxseed vs. aromatase inhibitors: breast tumor characteristics and prognosis
    Susan McCann; Fiscal Year: 2009
    ..Used in postmenopausal women, aromatase inhibitors (AI) block the peripheral conversion of androgens to estrogen, effectively lowering the estradiol available ..
  57. Predictors of Ovarian Function in Women Treated With Aromatase Inhibitors
    NORAH LYNN HENRY; Fiscal Year: 2012
    ..In this proposal we will identify those patients who can receive AI therapy safely, which will enable more personalized treatment decisions. ..
  58. Female Hormones and Vision
    Alvin Eisner; Fiscal Year: 2006
    ..clinical emphasis will be on 2 types of medications - selective estrogen receptor modulators (SERMS) and aromatase inhibitors. Both are used as adjuvant therapy for early-stage breast cancer, or are likely to be used for this purpose ..
  59. MECHANISMS OF INFERTILITY IN ENDOMETRIOSIS
    Serdar Bulun; Fiscal Year: 2002
    ..in baboon endometriotic lesions will be determined in response to various hormonal treatments including aromatase inhibitors. The second specific aim is to determine the mechanism of infertility associated with endometriosis and the ..
  60. BIOCHEMICAL PROBES OF THE ACTIVE SITE OF AROMATASE
    ROBERT BRUEGGEMEIER; Fiscal Year: 1993
    ..this competing renewal application will continue and extend investigations on the utilization of selected aromatase inhibitors as biochemical tools in studying the active site of aromatase. Investigations by the P.I...
  61. Association of breast cancer and its therapies with fracture
    Joan Neuner; Fiscal Year: 2009
    ..Finally, advances in adjuvant hormonal therapy with the introduction of aromatase inhibitors (AIs) suggest that osteoporosis will become a greater problem in the future...
  62. A Novel Long-Lived 41Ca Marker To Assess Bone Turnover For Breast Cancer Patients
    Susanta Hui; Fiscal Year: 2009
    ..in urine will offer (a) early detection of the accelerated bone resorption that result from the use of aromatase inhibitors, and (b) dynamic monitoring of the bone formation process due to antiresorptive drug intervention...
  63. NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY
    PH D SERRERO; Fiscal Year: 2012
    b>Aromatase Inhibitors (AI) are the preferred hormonal treatment for estrogen receptor positive Breast Cancer (BC) in postmenopausal women and are used to treat approximately 140,000 patients annually in the US...
  64. Treatment effects on hormones in the breast
    Robert Chatterton; Fiscal Year: 2005
    ..The effects of tamoxifen and aromatase inhibitors on estrogen-induced proteins cathepsin D and trefoil family factor-1 (TFF1) will be determined in breast ..
  65. STRUCTURE-FUNCTION OF STEROIDOGENIC CYTOCHROMES P-450
    John Shively; Fiscal Year: 1990
    ..The adult rats will be treated with aromatase inhibitors to study their possible affect on mRNA levels...
  66. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2005
    ..is expressed both in epithelial and stromal cells; and preneoplastic changes can be abrogated with aromatase inhibitors without affecting normal physiology...
  67. Development and validation of predictors of endocrine treatment sensitivity
    Christos Hatzis; Fiscal Year: 2007
    ..be used either individually or sequentially, but also with a wider cost range between generic tamoxifen and aromatase inhibitors that can effect treatment decisions...
  68. AROMATASE INHIBITORS: SKELETAL EFFECTS AND THE ROLE OF CYP19 GENE POLYMORPHISMS
    Reina Villareal; Fiscal Year: 2007
    ..of estrogen receptor positive (ER+) breast cancer has recently been challenged by a newer class drugs, the aromatase inhibitors, which are found to have superior efficacy over tamoxifen with better side-effect profile...
  69. Pharmacogenetics Research Network and Knowledge Base
    David Flockhart; Fiscal Year: 2009
    ..involvement of genetically polymorphic drug metabolizing enzymes in the human metabolism of the available aromatase inhibitors: letrozole, exemestane and anastrozole in vitro...